(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(-1.16%) $1.619
(-0.37%) $2 338.40
(0.82%) $27.48
(0.49%) $926.60
(-0.19%) $0.933
(-0.25%) $11.00
(-0.27%) $0.798
(0.00%) $92.17
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...
Stats | |
---|---|
Šios dienos apimtis | 136.00 |
Vidutinė apimtis | 594.00 |
Rinkos kapitalizacija | 135.19B |
EPS | €0 ( 2024-04-24 ) |
Kita pelno data | ( €0 ) 2024-05-01 |
Last Dividend | €2.13 ( 2023-08-17 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.63 |
ATR14 | €0.724 (0.29%) |
Amgen Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Amgen Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €28.19B |
Bruto pelnas: | €19.74B (70.02 %) |
EPS: | €12.56 |
FY | 2023 |
Pajamos: | €28.19B |
Bruto pelnas: | €19.74B (70.02 %) |
EPS: | €12.56 |
FY | 2022 |
Pajamos: | €26.32B |
Bruto pelnas: | €19.92B (75.66 %) |
EPS: | €12.18 |
FY | 2021 |
Pajamos: | €25.98B |
Bruto pelnas: | €19.53B (75.16 %) |
EPS: | €9.74 |
Financial Reports:
No articles found.
Amgen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.940 (N/A) |
€1.940 (N/A) |
€2.13 (N/A) |
€2.13 (N/A) |
€2.13 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.280 | 2011-08-16 |
Last Dividend | €2.13 | 2023-08-17 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | €56.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.22 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.55 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
JNJ.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
TA1.DE | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% | |
MMM.DE | Ex Dividend Junior | 2023-08-18 | Quarterly | 0 | 0.00% | |
4I1.DE | Ex Dividend Knight | 2023-09-26 | Quarterly | 0 | 0.00% | |
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
OMV.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% | |
AMG.DE | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.238 | 1.500 | 5.23 | 7.85 | [0 - 0.5] |
returnOnAssetsTTM | 0.0691 | 1.200 | 7.70 | 9.23 | [0 - 0.3] |
returnOnEquityTTM | 1.033 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.678 | -1.000 | 3.22 | -3.22 | [0 - 1] |
currentRatioTTM | 1.649 | 0.800 | 6.75 | 5.40 | [1 - 3] |
quickRatioTTM | 1.027 | 0.800 | 8.67 | 6.93 | [0.8 - 2.5] |
cashRatioTTM | 0.595 | 1.500 | 7.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.665 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3.15 | 1.000 | 9.94 | 9.94 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 3.12 | 6.24 | [0 - 20] |
debtEquityRatioTTM | 10.37 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.663 | 1.663 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.321 | 1.000 | 5.57 | 5.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.131 | 1.000 | -0.383 | -0.383 | [0.2 - 2] |
assetTurnoverTTM | 0.290 | 0.800 | -1.399 | -1.119 | [0.5 - 2] |
Total Score | 10.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.50 | 1.000 | 7.93 | 0 | [1 - 100] |
returnOnEquityTTM | 1.033 | 2.50 | 3.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 5.41 | 6.24 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
payoutRatioTTM | 0.678 | 1.500 | 3.22 | -3.22 | [0 - 1] |
pegRatioTTM | -5.58 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.300 | 1.000 | 4.99 | 0 | [0.1 - 0.5] |
Total Score | 4.55 |
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.